Preparation and evaluation of paclitaxel-containing liposomes

Pharmazie

Volumn 62, Issue 2, 2007, Pages 126-132

  Holvoet, C ^a   Vander Heyden, Y ^a   Lories, G ^a   Plaizier Vercammen, J ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CASTOR OIL; LIPOSOME; PACLITAXEL;

ANAPHYLAXIS; ARTICLE; BRONCHOSPASM; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HYPOTENSION; NEPHROTOXICITY; NEUROTOXICITY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZENE DERIVATIVES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; EXCIPIENTS; HYDROGEN PEROXIDE; LIPOSOMES; OXIDATION-REDUCTION; PACLITAXEL; PARTICLE SIZE; POLYETHYLENE GLYCOLS;

EID: 33847118637     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2007.2.6093     Document Type: Article

References (47)

1. AHFS, American Hospital Formulary Service (2002), Drug Information. In: Gerald K (ed.) American Society of Health-system Pharmacists, Bethesda, MD, USA, p. 1114-1115.
2. Arbuck SG, Christian MC, Fisherman JS, Cazenave LA, Sarosy G, Suffness M, Adams J, Canetta R, Cole KE, Friedman MA (1993) Clinical development of Taxol. J Natl Cancer Inst: Monographs 15: 11-24.
3. Ausborn M, Nuhn P, Schreier H (1992) Stabilization of liposomes by freeze-thaw- and lyophilization techniques: problems and opportunities. Eur J Pharm Biopharm 38: 133-139.
4. AVGI, Algemene vereniging van de Geneesmiddelenindustrie (General association of the drugs industry) (2001) In: Claessens P (ed.), MediMedia Belgium, Brussels, Belgium, p. 1641-1643.
5. Balasubramanian SV, Straubinger RM (1994) Taxol-lipid interactions: Taxol-dependent effects on the physical properties of model membranes. Biochem 33: 8941-8947.
6. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917.
7. Cserhati T, Hollo J (1994) Interaction of Taxol and other anticancer drugs with hydroxypropyl-β-cyclodextrin. Int J Pharm 108: 69-75.
8. Dordunoo S, Burt HM (1996) Solubility and stability of taxol: effect of buffers and cyclodextrins. Int J Pharm 133: 191-201.
9. rd edition supplement, Council of Europe, Strasbourg, France.
10. Gabriëls M, Cirunay J, Alafandy M, Brisaert M, Detaevenier M, Camu F, Plaizier-Vercammen J (2000) Determination of hydroperoxides in liposomes by the modified IDF and the modified Tiron methods. J AOAC Int 83: 589-596.
11. Gabriëls M, Camu F, Plaizier-Vercammen J (2002) Improved thin layer chromatographic method for the separation of cholesterol, egg phosphatidylcholine, and their degradation products J AOAC Int 85: 1273-1287.
12. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G, Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans. J Clin Oncol 13: 180-190.
13. 2 as a 3-hour infusion. Clin Drug Invest 9: 344-353.
14. Jiang Z-Y, Hunt JV, Wolff SP (1992) Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoprotein. Anal Biochem 202: 384-389.
15. Kearns CM (1997) Pharmacokinetics of the taxanes. Pharmacotherapy. Suppl. 17: 105S-109S.
16. KNMP, Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie (1999), Informatorium Medicamentorum, 's Gravenhage, The Netherlands, p. 678.
17. Lasic DD, Papahadjopoulos D (1998) Cancer therapy, in: Lasic and Papahadjopoulos (eds.), Medical applications of liposomes, Elsevier Science, Amsterdam, The Netherlands, p. 221-346.
18. Leikin JB, Paloucek FP (1996-1997) Poisoning & toxicology handbook 2° ed., Lexicomp's clinical reference library, Lexi-comp inc. (Cleveland) and Am. Pharm. Ass., p. 589-599 and p. 1159-1160.
19. Liggings RT, Hunter WL, Burt HM (1997) Solid-state characterization of paclitaxel. J Pharm Sci 86: 1458-1463.
20. Lubejko BG, Sartorius SE (1993) Nursing considerations in paclitaxol (Taxol®) administration. Semin Oncol 20: 26-30.
21. Macdonald RC, Macdonald RI (1993) Applications of freezing and thawing in liposome technology, in Gregoriadis G (ed.) Liposomes as drug carriers: trends and progress. Wiley, Chichester, Sussex. p. 209-223.
22. Malingré MM, Meerum-Terwoght JM, Beijnen JH (1999) Clinical pharmacology of oral paclitaxel in a dose escalating study. Proc Am Soc Clin Oncol 18: 637.
23. nd ed., Pharmaceutical Press, London, UK. p. 556-557.
24. Mayer LD, Hope MJ, Cullis PR, Janoff AS (1985) Solute distributions and trapping efficiences observed in freeze-thawed multilamellar vesicles. Biochem Biophys Acta 817: 193-196.
25. Meerum-Terwoght JM, Beijnen JH, Ten Bokkel HWW, Rosing H, Schellens JH (1998) Co-administration of oral cyclosporin A enables oral therapy with paclitaxel. Lancet 352: 285-285.
26. Merisko-Liversidge E, Sarpotdar P, Bruno J, Hajj S, Wei L, Peltier N, Shaw JM, Pugh S, Polin L, Jones J, Corbett T, Cooper E, Liversidge GG (1996) Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res 13: 272-278.
27. Monroe E, Wani MC (1995) Paclitaxel: from discovery to clinic. In: Georg GI, Chenn TT, Ojima I, Vyas DM (eds.), ACS symposiums series 583 "Taxane anticancers agents: basic science and current status", Am. Chem. Soc. Washington DC, p. 18-30.
28. Needham D, Sarpal RS (1998) Binding of paclitaxel to lipid interfaces: correlations with interface compliance. J Liposome Res 8: 147-163.
29. New RRC (1990) Liposomes, a Practical Approach. In: New RRC (ed.), IRL Press, Oxford University, Oxford, UK. p. 19, 113-118 and 257.
30. Pearson S, Trissel LA (1993) Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components. Am J Hosp Pharm 50: 1405-1409.
31. Pfeifer RW, Hale KN, Cronquist SE, Daniels M (1993) Letters: Precipitation of paclitaxel during infusion by pump. Am J Hosp Pharm 50: 2518-2521.
32. Ramaswamy M, Zhang X, Burt HM, Wasan KM (1997) Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J Pharm Sci 86: 460-464.
33. Ringel I, Horwitz SB (1987) Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium. J Pharmacol Exp Ther 242: 692-698.
34. nd ed., CRC Press, Boca Raton, FL. p. 253-270.
35. Sharma A, Mayhew E, Straubinger RM (1993) Antitumor effect of Taxol-containing liposomes in a Taxol-resistant murine tumor model. Cancer Res 53: 5877-5881.
36. Sharma A, Straubinger RM, Ojima I, Bernacki RJ (1995a) Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J Pharm Sci 84: 1400-1404.
37. Sharma US, Balasubramanian SV, Straubinger RM (1995b) Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. J Pharm Sci 84: 1223-1230.
38. Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A, Bernacki RJ (1997) Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Cancer 71: 103-107.
39. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56: 2112-2115.
40. Straubinger R, Sharma A, Sharma S (1995a) Chapter 8: Pharmacology and antitumor effect of novel paclitaxel formulations. In: Georg GI, Chenn TT, Ojima I, Vyas DM (eds.), ACS symposiums series 583 "Taxane anticancers agents: basic science and current status", Am. Chem. Soc. Washington DC, p. 111-123.
41. Straubinger RM, Sharma A, Murray M, Mayhew E (1995b) Novel Taxol formulations: Taxol-containing liposomes. J Nat Cancer Inst: Monographs 15: 69-78.
42. Suffness M (1993) Taxol: from discovery to therapeutic use. Annual Rep Med Chem 28: 305-314.
43. Szente L, Vikmon M, Szeman J, Otta K (1999) Methyl-β-cyclodextrin/ paclitaxel aqueous solutions: a tool to test Cremophor-free paclitaxel. STP Pharma Sci 9: 243-247.
44. Tarr B, Yalkowsky SH (1987a) A new parenteral vehicle for the administration of some poorly water soluble anti-cancer drugs. J Parent Sci Tech 41: 31-33.
45. Tarr B, Sambandan TG, Yalkowsky SH (1987b) A new parenteral emulsion for the administration of Taxol. Pharm Res 4: 162-165.
46. Trissel LA, Bready BB (1992) Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 49: 1716-1719.
47. Walle T, Walle UK, Kumar GN, Bhalla KN (1995) Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 23: 506-512.